Literature DB >> 28344892

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.

Brooke E Howitt1, Kyle C Strickland1, Lynette M Sholl1, Scott Rodig1, Lauren L Ritterhouse1, Dipanjan Chowdhury2, Alan D D'Andrea2, Ursula A Matulonis3, Panagiotis A Konstantinopoulos3.   

Abstract

Clear cell ovarian carcinoma (CCOC) represents a distinct histologic subtype of ovarian cancer associated with significantly worse prognosis across all stages and no effective therapeutic options. Here, we report a rare but clinically important cohort of CCOCs with microsatellite instability (MSI) (MSI-CCOCs), which are highly immunogenic and may thus be very responsive to immune checkpoint blockade. CCOCs with MSI exhibit a significantly higher number of CD8+ TILs, higher CD8+/CD4+ ratio, and higher PD-1+ TILs compared with microsatellite stable (MSS) CCOCs and compared with high grade serous ovarian cancers, which are the most common histologic subtype of ovarian cancer. Of note, PD-L1 expression in tumor cells or immune cells was noted in all cases of CCOCs with MSI. These observations open an alternative therapeutic avenue for a fraction of patients with CCOC and argue for the routine testing of CCOCs for MSI, a test that is not currently routinely performed.

Entities:  

Keywords:  Clear cell ovarian cancer; PD-1; PD-L1; immunotherapy; microsatellite instability; tumor-infiltrating lymphocytes

Year:  2017        PMID: 28344892      PMCID: PMC5353914          DOI: 10.1080/2162402X.2016.1277308

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  8 in total

1.  Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

Authors:  Brooke E Howitt; Sachet A Shukla; Lynette M Sholl; Lauren L Ritterhouse; Jaclyn C Watkins; Scott Rodig; Elizabeth Stover; Kyle C Strickland; Alan D D'Andrea; Catherine J Wu; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  JAMA Oncol       Date:  2015-12       Impact factor: 31.777

2.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Takafumi Ikeda; Manabu Minami; Atsushi Kawaguchi; Toshinori Murayama; Masashi Kanai; Yukiko Mori; Shigemi Matsumoto; Shunsuke Chikuma; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Akihiko Ueda; Yuko Hosoe; Satoshi Morita; Masayuki Yokode; Akira Shimizu; Tasuku Honjo; Ikuo Konishi
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

4.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Authors:  Nicolas J Llosa; Michael Cruise; Ada Tam; Elizabeth C Wicks; Elizabeth M Hechenbleikner; Janis M Taube; Richard L Blosser; Hongni Fan; Hao Wang; Brandon S Luber; Ming Zhang; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Cynthia L Sears; Robert A Anders; Drew M Pardoll; Franck Housseau
Journal:  Cancer Discov       Date:  2014-10-30       Impact factor: 39.397

5.  Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.

Authors:  David R Crotzer; Charlotte C Sun; Robert L Coleman; Judith K Wolf; Charles F Levenback; David M Gershenson
Journal:  Gynecol Oncol       Date:  2007-02-09       Impact factor: 5.482

Review 6.  Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Authors:  Xiangjiao Meng; Zhaoqin Huang; Feifei Teng; Ligang Xing; Jinming Yu
Journal:  Cancer Treat Rev       Date:  2015-11-10       Impact factor: 12.111

7.  POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.

Authors:  Tjalling Bosse; David N Church; Inge C van Gool; Florine A Eggink; Luke Freeman-Mills; Ellen Stelloo; Emanuele Marchi; Marco de Bruyn; Claire Palles; Remi A Nout; Cor D de Kroon; Elisabeth M Osse; Paul Klenerman; Carien L Creutzberg; Ian Pm Tomlinson; Vincent Thbm Smit; Hans W Nijman
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

8.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

Authors:  Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  Oncotarget       Date:  2016-03-22
  8 in total
  26 in total

Review 1.  Review of Immune Therapies Targeting Ovarian Cancer.

Authors:  Cong Ava Fan; Jocelyn Reader; Dana M Roque
Journal:  Curr Treat Options Oncol       Date:  2018-11-14

Review 2.  The roles of pathology in targeted therapy of women with gynecologic cancers.

Authors:  Rajmohan Murali; Rachel N Grisham; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

3.  Harnessing mutual exclusivity between TP53 and ARID1 A mutations.

Authors:  Shuai Wu; Nail Fatkhutdinov; Rugang Zhang
Journal:  Cell Cycle       Date:  2017       Impact factor: 4.534

4.  The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.

Authors:  Hiroko Matsuura; Morikazu Miyamoto; Taira Hada; Hiroki Ishibashi; Hideki Iwahashi; Soichiro Kakimoto; Rie Suzuki; Tsubasa Ito; Jin Suminokura; Hitoshi Tsuda; Masashi Takano
Journal:  Arch Gynecol Obstet       Date:  2022-05-04       Impact factor: 2.344

5.  Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics.

Authors:  Xinyu Li; Lan Zhang; Chunxiao Wang; Junli Huang; Jinfeng Zhu; Yisen Huang; Yifeng Chen; Jing Jia; Guozhong Jiang
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 6.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

7.  Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

Authors:  Panagiotis A Konstantinopoulos; Barbara Norquist; Christina Lacchetti; Deborah Armstrong; Rachel N Grisham; Paul J Goodfellow; Elise C Kohn; Douglas A Levine; Joyce F Liu; Karen H Lu; Dorinda Sparacio; Christina M Annunziata
Journal:  J Clin Oncol       Date:  2020-01-27       Impact factor: 44.544

8.  Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Authors:  Holly Butler; Omar Saulat; Barbara-Ann Guinn
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

Review 9.  Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.

Authors:  Xinxin Zhu; Jinghe Lang
Journal:  J Gynecol Oncol       Date:  2017-06-05       Impact factor: 4.401

Review 10.  Precision medicine becomes reality-tumor type-agnostic therapy.

Authors:  Li Yan; Wei Zhang
Journal:  Cancer Commun (Lond)       Date:  2018-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.